Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China.
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Aug 2017
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Pharmacokinetics
- 17 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 17 Aug 2015 Planned primary completion date changed from 1 May 2013 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 17 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.